PDL BioPharma, Inc.
PDLI
PDLI was delisted on the 30th of December, 2020.
187 hedge funds and large institutions have $387M invested in PDL BioPharma, Inc. in 2017 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 59 increasing their positions, 60 reducing their positions, and 26 closing their positions.
15% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 26
1% more funds holding
Funds holding: 186 → 187 (+1)
2% less repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 60
17% less capital invested
Capital invested by funds: $467M → $387M (-$80.1M)
52% less call options, than puts
Call options by funds: $186K | Put options by funds: $388K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
+$5.16M |
| 2 |
State Street
Boston,
Massachusetts
|
+$4.41M |
| 3 |
Morgan Stanley
New York
|
+$3.18M |
| 4 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
+$3.17M |
| 5 |
MCM
Matarin Capital Management
New York
|
+$3.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$5.97M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$3.91M |
| 3 |
Renaissance Technologies
New York
|
-$2.6M |
| 4 |
Bank of New York Mellon
New York
|
-$2.48M |
| 5 |
OSAM
O'Shaughnessy Asset Management
Stamford,
Connecticut
|
-$1.96M |
PDLI Hedge Fund Activity: Q4 2017 in Review
187 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in PDL BioPharma, Inc. (PDLI) for Q4 2017, worth a combined $387M — down 17% from $467M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new PDLI positions and 26 closed out — a net gain of 4 holders — while 59 added to existing stakes and 60 trimmed.
The largest buyer was Dimensional Fund Advisors, adding an estimated $5.16M. The largest seller was Millennium Management, cutting an estimated $5.97M.
- 187 institutional investors held PDL BioPharma, Inc. (PDLI) as of Q4 2017, up from 186 in Q3 2017.
- Funds reported $387M of PDL BioPharma, Inc. stock for Q4 2017, down 17% quarter-over-quarter.
- 30 funds opened new PDL BioPharma, Inc. positions in Q4 2017 and 26 closed out, a net change of +4 holders.
- The largest PDL BioPharma, Inc. buyer in Q4 2017 was Dimensional Fund Advisors, an estimated $5.16M added.
- The largest PDL BioPharma, Inc. seller in Q4 2017 was Millennium Management, an estimated $5.97M sold.
Based on aggregated 13F filings for Q4 2017.